Skip to main content
OpenTrials

Clinical trial condition

Rubella

Explore clinical trials studying Rubella. Study availability and eligibility vary by location and protocol.

68 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Rubella trial results

Completed

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

NCT05630846

Conditions
Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Bellflower, California, United States
  • GSK Investigational Site Huntington Park, California, United States
View all 47 locations
View Trial Details
Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

NCT02184572

Conditions
Infections, Measles, Measles-Mumps-Rubella Vaccine, +16 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Fayetteville, Arkansas, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
View all 95 locations
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

NCT01681992

Conditions
Infections, Measles, Measles-Mumps-Rubella Vaccine, +15 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
View all 81 locations
View Trial Details
Completed

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

NCT00861744

Conditions
Infections, Measles, Measles-Mumps-Rubella Vaccine, +15 more
Locations
  • GSK Investigational Site Tuscaloosa, Alabama, United States
  • GSK Investigational Site Conway, Arkansas, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
View all 48 locations
View Trial Details

Related conditions